Rafael Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Fourth Quarter and Full Year Fiscal 2026 Financial Results | 28 Oct 2026 |
| First Quarter Fiscal 2027 Financial Results | 11 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Phase 3 TransportNPC™ Trial Topline Data Release QuarterlyTarget: Preliminary topline results expected in Q3 calendar 2026
New Drug Application (NDA) Submission for Trappsol® Cyclo™ QuarterlyTarget: Submission to the FDA in H2 calendar 2026
Cash and Cash Equivalents Quarterly30.5MTarget: Sufficient liquidity to fund operations through NDA preparation and review
Watch Items
- Topline efficacy and safety data from the main cohort of the Phase 3 TransportNPC™ trialTrigger: Unblinding and announcement of results in H2 calendar 2026Action: Evaluate clinical endpoints (e.g., CGI scores, clinical severity scales) to assess probability of FDA approval.
- Cash burn rate and potential capital raising activitiesTrigger: Cash balance dropping below $15 million without a commercial partnerAction: Assess dilution risk or terms of potential licensing/partnership agreements to fund commercial launch.
- Competitive landscape dynamics in the Niemann-Pick Disease Type C (NPC) marketTrigger: Market uptake of approved therapies (Miplyffa by Zevra and Aqneursa by IntraBio)Action: Analyze market penetration of existing treatments to refine commercial projections for Trappsol® Cyclo™.
Research as of 19 Jun 2026